NCT07472361

A Study of ENX-104 in Healthy Participants

A Randomized, Open-Label, Three-Way Crossover Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of ENX-104 Administered Orally as a Solution Fasted, a Tablet Fasted, or a Tablet With a High Fat Meal in Healthy Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Engrail Therapeutics INC · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

The study is designed to evaluate the relative bioavailability, safety, and tolerability of a single dose of ENX-104 administered orally as a solution fasted, a tablet fasted, or a tablet with a high fat meal in healthy participants

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	ENX-104	Tablets
DRUG	ENX-104	Oral solution

Timeline

• Start date: 2026-02-25
• Primary completion: 2026-03-01
• Completion: 2026-03-01
• First posted: 2026-03-16
• Last updated: 2026-03-16

Locations

1 site across 1 country: United Kingdom